Clinical Trial Update: Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating unacylated ghrelin for improving function in Peripheral Artery Disease (PAD) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Drugs mentioned

• Unacylated Ghrelin (unacylated ghrelin)

Snippet

Sponsor: Northwestern University | Conditions: Peripheral Artery Disease, PAD | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-12